Cooper Companies Inc (NYSE:COO) – Analysts at Northcoast Research boosted their Q3 2018 earnings per share estimates for Cooper Companies in a research note issued to investors on Wednesday. Northcoast Research analyst D. Keiser now forecasts that the medical device company will post earnings per share of $3.11 for the quarter, up from their prior estimate of $3.05. Northcoast Research also issued estimates for Cooper Companies’ Q4 2018 earnings at $3.19 EPS, FY2018 earnings at $11.87 EPS, Q1 2019 earnings at $2.76 EPS, Q2 2019 earnings at $3.22 EPS, Q3 2019 earnings at $3.32 EPS, Q4 2019 earnings at $3.42 EPS and FY2019 earnings at $12.72 EPS.
Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus restated a “buy” rating and issued a $265.00 target price (down previously from $275.00) on shares of Cooper Companies in a research report on Friday, December 8th. KeyCorp restated a “hold” rating on shares of Cooper Companies in a research report on Friday, October 20th. Oppenheimer set a $250.00 target price on Cooper Companies and gave the company a “hold” rating in a research report on Friday, December 8th. Zacks Investment Research downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets restated a “buy” rating and issued a $272.00 target price on shares of Cooper Companies in a research report on Friday, October 13th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Cooper Companies presently has a consensus rating of “Buy” and a consensus price target of $259.70.
Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Thursday, December 7th. The medical device company reported $2.65 EPS for the quarter, topping the Zacks’ consensus estimate of $2.64 by $0.01. Cooper Companies had a return on equity of 16.02% and a net margin of 17.43%. The firm had revenue of $561.50 million for the quarter, compared to the consensus estimate of $558.86 million. During the same quarter last year, the business posted $2.28 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Cooper Companies by 3.3% in the second quarter. Vanguard Group Inc. now owns 4,938,181 shares of the medical device company’s stock valued at $1,182,298,000 after buying an additional 156,449 shares in the last quarter. BlackRock Inc. grew its stake in Cooper Companies by 4.5% during the 2nd quarter. BlackRock Inc. now owns 3,210,032 shares of the medical device company’s stock worth $768,546,000 after purchasing an additional 138,395 shares in the last quarter. Janus Henderson Group PLC grew its stake in Cooper Companies by 0.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,185,268 shares of the medical device company’s stock worth $518,147,000 after purchasing an additional 9,477 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its stake in Cooper Companies by 2.2% during the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 1,252,938 shares of the medical device company’s stock worth $297,084,000 after purchasing an additional 26,688 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its stake in Cooper Companies by 47.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 636,882 shares of the medical device company’s stock worth $151,011,000 after purchasing an additional 206,003 shares in the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Robert S. Weiss sold 32,500 shares of Cooper Companies stock in a transaction on Monday, December 18th. The stock was sold at an average price of $224.70, for a total value of $7,302,750.00. Following the completion of the sale, the chief executive officer now directly owns 119,111 shares of the company’s stock, valued at $26,764,241.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Allan E. Rubenstein sold 500 shares of Cooper Companies stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $222.00, for a total value of $111,000.00. Following the completion of the sale, the director now directly owns 6,590 shares of the company’s stock, valued at $1,462,980. The disclosure for this sale can be found here. Insiders sold 54,385 shares of company stock valued at $12,289,463 over the last ninety days. Insiders own 1.60% of the company’s stock.
The firm also recently announced a semiannual dividend, which will be paid on Friday, February 9th. Shareholders of record on Tuesday, January 23rd will be given a $0.03 dividend. The ex-dividend date of this dividend is Monday, January 22nd. This represents a yield of 0.03%. Cooper Companies’s dividend payout ratio is currently 0.80%.
TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/01/18/q3-2018-eps-estimates-for-cooper-companies-inc-coo-lifted-by-northcoast-research.html.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.